slt

Mark Turco

Global Chief Medical Officer & Executive Vice President of Research & Development

Experience and Expertise

Mark Turco, M.D., FACC, is the Global Chief Medical Officer and Executive Vice President of Research & Development for Sirtex. With more than three decades of experience as a board-certified interventional cardiologist, clinical researcher, healthcare executive and innovationist, Mark serves as the company’s principal medical expert and corporate leader of medical and clinical affairs. He is also responsible for continuing to develop the strategic vision for Sirtex’s clinical trial portfolio and building out the company’s R&D function.

Prior to joining Sirtex in June 2020, Mark served as Chief Innovation and Corporate Outreach Officer for the University of Pennsylvania. Before that role, Mark was the Vice President & Chief Medical Officer for Medtronic’s Aortic, Peripheral & Vascular Divisions, where he led a large team responsible for clinical, health economics, and physician training. Prior to Medtronic, Mark served as Director of The Center for Cardiac & Vascular Research at Washington Adventist Hospital, where he led a cardiovascular translational research center and worked as the principal investigator on large-scale medical device and pharmaceutical trials.

Mark earned a bachelor’s degree in biology from the University of Pennsylvania and a doctorate of medicine from George Washington University. He then completed his residency in general internal medicine from George Washington University Medical Center in Washington D.C., followed by a fellowship in cardiology and interventional cardiology from Temple University Hospital in Philadelphia, Pennsylvania.




slt
Kevin R. Smith
CEO

slt
Paul Andreassi
Executive Vice President of Global Quality Assurance

slt
Jesse Hansen
Global Head of Marketing

slt
Francis Jannot
Executive Vice President of International Sales

slt
Cathleen Lowndes
Chief Human Resources Officer

slt
Amy Pan
Chief Financial Officer

slt
Suki Shergill
Executive Vice President, Global Pricing & Market Access

slt
Kevin P. Smith
General Counsel & Executive Vice President, Business Development

slt
Grant Spindler
Global Head of Operations

slt
MaryLou Stroumbos
Executive Vice President, Regulatory Affairs

slt
Mark Turco
Global Chief Medical Officer & Executive Vice President of Research & Development



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Click here to view our Technical Bulletin.

Ok